Acumen Pharmaceuticals Inc

10-Year Study

ABOS.US · Healthcare · US · Common Stock

Executive Summary: Acumen Pharmaceuticals Inc has compounded at -30.8% annually over the last 10 years, with a maximum drawdown of 94.3% and an annualized volatility of 166.7%.

1Y CAGR
+187.9%
3Y CAGR
-18.7%
5Y CAGR
-30.8%
10Y CAGR
-30.8%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
94.3%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.03
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.06
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
89.4%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +27.5%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2024 · -55.2%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
40%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
202623.220.8-24.814.0————————27.5%
2025-12.8-14.7-14.12.7-9.713.720.7-2.925.729.2-14.912.222.7%
2024-17.235.5-6.0-20.5-8.7-17.736.4-17.0-9.516.1-21.2-24.2-55.2%
202321.7-19.8-23.0-4.927.7-2.453.8-18.6-31.1-54.928.360.0-28.9%
2022-24.314.5-33.3-1.3-8.332.815.74.676.3-31.0-17.9-4.9-20.1%
2021———————15.8-17.1-5.5-43.8-14.4-56.3%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 166.7%. The dominant macroeconomic risk driver is SHV.US, accounting for 70.2% of variance. Idiosyncratic stock-specific factors contribute 12.4%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2021-07-0110000
2021-08-0111576.22739018088
2021-09-019599.483204134365
2021-10-019076.227390180879
2021-11-015103.359173126615
2021-12-014366.9250645994825
2022-01-013307.4935400516797
2022-02-013785.529715762274
2022-03-012525.839793281654
2022-04-012493.540051679586
2022-05-012286.8217054263564
2022-06-013036.1757105943157
2022-07-013514.21188630491
2022-08-013675.7105943152455
2022-09-016479.328165374676
2022-10-014470.284237726099
2022-11-013669.2506459948313
2022-12-013488.3720930232557
2023-01-014244.186046511628
2023-02-013404.392764857881
2023-03-012622.739018087855
2023-04-012493.540051679586
2023-05-013184.754521963824
2023-06-013107.2351421188628
2023-07-014780.361757105943
2023-08-013888.8888888888882
2023-09-012680.878552971576
2023-10-011208.0103359173127
2023-11-011550.3875968992247
2023-12-012480.6201550387595
2024-01-012054.263565891473
2024-02-012784.237726098191
2024-03-012616.2790697674413
2024-04-012080.1033591731266
2024-05-011899.2248062015503
2024-06-011563.3074935400514
2024-07-012131.782945736434
2024-08-011770.0258397932816
2024-09-011602.0671834625323
2024-10-011860.4651162790697
2024-11-011466.40826873385
2024-12-011111.111111111111
2025-01-01968.9922480620154
2025-02-01826.8733850129199
2025-03-01710.5943152454781
2025-04-01729.9741602067182
2025-05-01658.9147286821706
2025-06-01749.3540051679586
2025-07-01904.392764857881
2025-08-01878.5529715762275
2025-09-011104.6511627906975
2025-10-011427.6485788113694
2025-11-011214.470284237726
2025-12-011363.049095607235
2026-01-011679.5865633074936
2026-02-012028.4237726098193
2026-03-011524.5478036175707
2026-04-011737.7260981912143
Annual Return Matrix
YearAnnual Return
2022-0.20118343195266264
2023-0.288888888888889
2024-0.5520833333333333
20250.2267441860465116
20260.2748815165876777
Total Factor Risk
1.6669506971062908
VTI.US Exposure
0.029261630968234854
VEA.US Exposure
0.00863468590209824
VWO.US Exposure
-0.0008131999475862243
QQQ.US Exposure
0.010915590808050626
VTV.US Exposure
0.0006276430815512062
IJR.US Exposure
0.05152622999305513
QUAL.US Exposure
0.0001169201921613164
SHV.US Exposure
0.7023427144413654
TLT.US Exposure
0.03171417687617953
LQD.US Exposure
0.0071138244136264685
HYG.US Exposure
-0.0002819177565594123
GLD.US Exposure
0.013884800493102945
USO.US Exposure
0.002317703256942761
VNQ.US Exposure
-0.0019672101446107544
BTC-USD.CC Exposure
0.0021478121213219688
CPER.US Exposure
-0.0010434902327680988
VIX.INDX Exposure
0.0005995858071170597
UUP.US Exposure
0.0035302913779546407
TIP.US Exposure
0.014892441987199731
Idiosyncratic Exposure
0.12447976636156248
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
166.7%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$195.0M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-2.5%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+34.5%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
20.2% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
0.34
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Acumen Pharmaceuticals Inc a high-risk investment?

Acumen Pharmaceuticals Inc (ABOS.US) has an annualized volatility of 166.7% and experienced a maximum drawdown of 94.3% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of ABOS.US?

Over the past 10 years, ABOS.US has generated a Compound Annual Growth Rate (CAGR) of -30.8%. It has had a positive return in 40% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Acumen Pharmaceuticals Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest